434 related articles for article (PubMed ID: 33543652)
21. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
[TBL] [Abstract][Full Text] [Related]
23. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
[TBL] [Abstract][Full Text] [Related]
24. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
25. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
26. Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak.
Tagliamento M; Spagnolo F; Poggio F; Soldato D; Conte B; Ruelle T; Barisione E; De Maria A; Del Mastro L; Di Maio M; Lambertini M
Eur J Clin Invest; 2020 Sep; 50(9):e13315. PubMed ID: 32535890
[TBL] [Abstract][Full Text] [Related]
27. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
28. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
29. Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu.
Leyfman Y; Erick TK; Reddy SS; Galwankar S; Nanayakkara PWB; Di Somma S; Sharma P; Stawicki SP; Chaudry IH
Shock; 2020 Oct; 54(4):438-450. PubMed ID: 32649367
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis.
Qian W; Ye Y; Zuo L; Song T; Xu Q; Wang Y; Qian J; Tian Y
Immunotherapy; 2021 Oct; 13(15):1271-1282. PubMed ID: 34431319
[TBL] [Abstract][Full Text] [Related]
31. Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review).
Vivarelli S; Falzone L; Torino F; Scandurra G; Russo G; Bordonaro R; Pappalardo F; Spandidos DA; Raciti G; Libra M
Int J Oncol; 2021 Feb; 58(2):145-157. PubMed ID: 33491759
[TBL] [Abstract][Full Text] [Related]
32. Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection.
Awadasseid A; Yin Q; Wu Y; Zhang W
Biomed Pharmacother; 2021 Oct; 142():111957. PubMed ID: 34339917
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Yatim N; Boussier J; Tetu P; Smith N; Bruel T; Charbit B; Barnabei L; Corneau A; Da Meda L; Allayous C; Baroudjian B; Jebali M; Herms F; Grzelak L; Staropoli I; Calmettes V; Hadjadj J; Peyrony O; Cassius C; LeGoff J; Kramkimel N; Aractingi S; Fontes M; Blanc C; Rieux-Laucat F; Schwartz O; Terrier B; Duffy D; Lebbé C
Sci Adv; 2021 Aug; 7(34):. PubMed ID: 34407944
[TBL] [Abstract][Full Text] [Related]
34. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
35. Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis.
Dumoulin DW; Gietema HA; Paats MS; Hendriks LEL; Cornelissen R
Front Oncol; 2020; 10():577696. PubMed ID: 33194697
[TBL] [Abstract][Full Text] [Related]
36. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.
Minkove SJ; Sun J; Li Y; Cui X; Cooper D; Eichacker PQ; Torabi-Parizi P
Rev Med Virol; 2022 Sep; 32(5):e2352. PubMed ID: 35416370
[TBL] [Abstract][Full Text] [Related]
38. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
39. Immune Targeted Therapies for COVID-19 Infection: A Narrative Review.
Forouzani-Haghighi B; Rezvani A; Vazin A
Iran J Med Sci; 2022 Jul; 47(4):291-299. PubMed ID: 35919074
[TBL] [Abstract][Full Text] [Related]
40. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
